Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up

MT Newswires Live

Yesterday

Neuren Pharmaceuticals (ASX:NEU) logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.

For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.

The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.

The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.tigermarketb.com/news/2662763421"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662763421\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662763421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 08:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662763421","market":"nz","top_or_hot":-1,"title":"Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.</p><p>For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.</p><p>The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.</p><p>The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals H1 Earnings Down; Royalty Income Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-26 08:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.</p><p>For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.</p><p>The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.</p><p>The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2662763421","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662763421","pubTimestamp":1787704117,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals  logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Neuren Pharmaceuticals H1 盈利下降；版税收入增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1},"content_text":"Neuren Pharmaceuticals (ASX:NEU) logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}